CONUT Score and CT-Derived Body Composition Parameters Predict Outcomes in Older Adults with AML and MDS Treated with Low-Intensity Therapy
In older adults with AML or MDS treated with low-intensity therapy, pre-treatment CONUT scores and CT-derived body composition parameters (specifically low skeletal muscle and subcutaneous adipose tissue indices) serve as significant predictors of inferior overall survival and increased risk of febrile neutropenia, supporting the routine integration of nutritional and body composition assessments in clinical care.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person is diagnosed with a blood cancer like acute myeloid leukemia or myelodysplastic neoplasms, the disease itself is only part of the story. These conditions strike most often in older adults, and the body's ability to withstand treatment depends heavily on the patient's overall physical condition. For decades, doctors have relied on a simple measure of body weight, known as body mass index, to gauge a patient's health. However, weight alone can be misleading; it does not distinguish between muscle, fat, or fluid, nor does it reveal the subtle signs of malnutrition that can leave a patient too weak to survive chemotherapy. In recent years, researchers have begun looking deeper, using blood tests to check for low levels of protein and immune cells, and using medical scans to measure the actual amount of muscle and fat in the body. The question driving this new line of inquiry is whether these detailed snapshots of a patient's physical state can predict who will survive treatment and who will face severe complications.
A team of researchers in Mexico City set out to answer this question by studying fifty-four older adults who had been diagnosed with these blood cancers and were treated with milder, low-intensity therapies rather than aggressive chemotherapy. The study focused on two specific tools: a score called the CONUT score, which calculates nutritional status based on blood protein, cholesterol, and immune cell counts, and a detailed analysis of body composition derived from CT scans taken at the level of the lower spine. The researchers wanted to see if these pre-treatment measurements could forecast how long patients would live and whether they would develop dangerous fevers caused by low white blood cell counts, a condition known as febrile neutropenia.
The results painted a clear picture of risk. The researchers found that the standard measure of body weight, body mass index, failed to separate patients into groups with different survival rates. A patient with a "normal" weight was just as likely to struggle as one with an "abnormal" weight. In contrast, the CONUT score proved to be a powerful predictor. Patients with a score higher than five, indicating significant nutritional impairment, faced a much shorter lifespan. The data showed that those with high scores survived a median of just 1.7 months, compared to 14.5 months for those with lower scores. When the researchers broke down the components of this score, they discovered that the driving force behind this poor outcome was low levels of albumin, a key protein in the blood, rather than cholesterol or immune cell counts. This suggests that in these specific patients, the body's protein reserves are a critical indicator of resilience.
The study also looked inside the body using CT scans, which allowed the team to measure the actual volume of muscle and fat tissue. Among the patients who had these scans available, the researchers found that having less muscle mass was a strong warning sign for early death. Similarly, having less subcutaneous fat, the layer of fat found just beneath the skin, was also linked to significantly worse survival rates. This finding challenges the common assumption that having more fat is always better for an older patient facing illness; in this case, a lack of this specific type of fat was a marker for frailty. Interestingly, the amount of visceral fat, which surrounds the internal organs, did not show a clear link to survival, highlighting that where fat is stored matters more than the total amount.
Perhaps the most surprising discovery concerned the relationship between fat and treatment side effects. While having less subcutaneous fat predicted a shorter life, having a large amount of this same fat was paradoxically linked to a higher risk of developing febrile neutropenia within the first three months of treatment. Patients with high levels of subcutaneous fat were far more likely to experience these severe infections than those with lower levels. The researchers suggest that this might be because fat tissue changes how drugs move through the body, potentially altering the concentration of medication in the blood, though this remains a hypothesis that needs further testing.
Ultimately, this research indicates that for older adults with these blood cancers, a simple check of body weight is not enough to understand their risk. Instead, a combination of blood tests to check protein levels and scans to measure muscle and fat provides a much clearer map of a patient's future. The study suggests that doctors should routinely include these detailed nutritional and body composition assessments before starting treatment. By identifying patients who are malnourished or have low muscle and fat reserves, medical teams might be able to intervene earlier, potentially improving how well patients tolerate their therapy and extending their lives. The findings do not offer a cure, but they provide a vital new lens through which to view the vulnerability of the aging body in the face of cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.